NO20062676L - Substituerte triazoler som natriumkanalblokkere - Google Patents

Substituerte triazoler som natriumkanalblokkere

Info

Publication number
NO20062676L
NO20062676L NO20062676A NO20062676A NO20062676L NO 20062676 L NO20062676 L NO 20062676L NO 20062676 A NO20062676 A NO 20062676A NO 20062676 A NO20062676 A NO 20062676A NO 20062676 L NO20062676 L NO 20062676L
Authority
NO
Norway
Prior art keywords
pain
alone
pharmaceutically acceptable
effective amount
compounds
Prior art date
Application number
NO20062676A
Other languages
English (en)
Inventor
Prasun K Chakravarty
Williams H Parsons
Michael H Fisher
Hyun Ok
Brenda Palucki
Min K Park
Bishan Zhou
Edward Gonzalez
Rosemary Sisco
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO20062676L publication Critical patent/NO20062676L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Anesthesiology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)

Abstract

Substituerte triazolforbindelser representert ved formel I, II eller III, eller et farmasøytisk akseptabelt salt derav. Farmasøytiske preparater omfatter en effektiv mengde av de foreliggende forbindelser, enten alene eller i kombinasjon med en eller flere andre terapeutisk aktive forbindelser, og en farmasøytisk akseptabel bærer. Fremgangsmåter for behandling av tilstander forbundet med eller forårsaket av natriumkanalaktivitet, inkludert for eksempel akutt smerte, kronisk smerte, innvollssmerte, inflammatorisk smerte, nevropatisk smerte, migrene, hodepine, migrenehodepine, epilepsi, irritabel tarmsyndrom, diabetisk nevropati, multippel sklerose, manisk depresjon, bipolar forstyrrelse, omfatter administrering av en effektiv mengde av de foreliggende forbindelser enten alene eller i kombinasjon med en eller flere andre terapeutisk aktive forbindelser. En fremgangsmåte for administrering av lokalanestesi omfatter administrering av en effektiv mengde av en forbindelse ifølge den foreliggende oppfinnelse, enten alene eller i kombinasjon med en eller flere andre terapeutisk aktive forbindelser, og en farmasøytisk akseptabel bærer.
NO20062676A 2003-11-10 2006-06-09 Substituerte triazoler som natriumkanalblokkere NO20062676L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51889003P 2003-11-10 2003-11-10
PCT/US2004/037280 WO2005047270A2 (en) 2003-11-10 2004-11-05 Substituted triazoles as sodium channel blockers

Publications (1)

Publication Number Publication Date
NO20062676L true NO20062676L (no) 2006-08-10

Family

ID=34590316

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062676A NO20062676L (no) 2003-11-10 2006-06-09 Substituerte triazoler som natriumkanalblokkere

Country Status (17)

Country Link
US (2) US20090074890A1 (no)
EP (1) EP1694654B1 (no)
JP (1) JP2007510741A (no)
KR (1) KR20060123739A (no)
CN (1) CN1922156A (no)
AT (1) ATE500234T1 (no)
AU (1) AU2004289694B2 (no)
BR (1) BRPI0416319A (no)
CA (1) CA2545254A1 (no)
DE (1) DE602004031667D1 (no)
IL (1) IL175522A0 (no)
IS (1) IS8438A (no)
NO (1) NO20062676L (no)
NZ (1) NZ547044A (no)
RU (1) RU2372339C2 (no)
WO (1) WO2005047270A2 (no)
ZA (1) ZA200603583B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY142651A (en) * 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
US20090074890A1 (en) * 2003-11-10 2009-03-19 Park Min K Substituted Triazoles as Sodium Channel Blockers
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
GB0603008D0 (en) * 2006-02-14 2006-03-29 Portela & Ca Sa Method
KR100808551B1 (ko) 2006-12-01 2008-03-03 한국생명공학연구원 트리아졸 유도체를 유효성분으로 함유하는 대사성 질환 예방 및 치료용 약학적 조성물
CN101679319B (zh) 2007-02-08 2014-07-09 辛塔医药品有限公司 用于治疗增生性病症如癌症的三唑类化合物
BR122015028990B8 (pt) * 2007-04-03 2017-12-26 Du Pont composto, composições fungicidas e método de controle de doenças das plantas
JP5586470B2 (ja) * 2007-10-25 2014-09-10 リバルシオ コーポレイション 静菌性または殺菌性組成物および方法
CA2703672A1 (en) * 2007-10-25 2009-04-30 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
AU2008326381B2 (en) * 2007-11-21 2014-10-23 Decode Genetics Ehf Biaryl PDE4 inhibitors for treating inflammation
EP2222639A1 (en) 2007-11-21 2010-09-01 Decode Genetics EHF Biaryl pde4 inhibitors for treating pulmonary and cardiovascular disorders
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531510B1 (en) 2010-02-01 2014-07-23 Novartis AG Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
ES2527849T3 (es) 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF
AR086554A1 (es) 2011-05-27 2014-01-08 Novartis Ag Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
EA201491990A1 (ru) 2012-05-03 2015-02-27 Новартис Аг L-малатная соль 2,7-диазаспиро[4.5]дец-7-иловых производных и их кристаллические формы в качестве агонистов грелиновых рецепторов

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1300055B1 (it) * 1998-04-17 2000-04-05 Boehringer Ingelheim Italia Eterocicli con anello a 5 termini difenil-sostituiti loro procedimento di preparazione e loro impiego come farmici
AR029489A1 (es) * 2000-03-10 2003-07-02 Euro Celtique Sa Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
JP5132861B2 (ja) * 2000-03-24 2013-01-30 ユーロ−セルティック エス． ア． ナトリウムチャネル遮断薬としてのアリール置換ピラゾール、トリアゾールおよびテトラゾール
AR037233A1 (es) * 2001-09-07 2004-11-03 Euro Celtique Sa Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento
MY142651A (en) * 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
US20060183897A1 (en) * 2003-03-18 2006-08-17 Chakravarty Prasun K Biaryl substituted triazoles as sodium channel blockers
US20090074890A1 (en) * 2003-11-10 2009-03-19 Park Min K Substituted Triazoles as Sodium Channel Blockers

Also Published As

Publication number Publication date
EP1694654A2 (en) 2006-08-30
CA2545254A1 (en) 2005-05-26
ATE500234T1 (de) 2011-03-15
NZ547044A (en) 2010-05-28
US20060020006A1 (en) 2006-01-26
AU2004289694A1 (en) 2005-05-26
EP1694654B1 (en) 2011-03-02
ZA200603583B (en) 2007-08-29
RU2006120426A (ru) 2007-12-27
US7459475B2 (en) 2008-12-02
RU2372339C2 (ru) 2009-11-10
IS8438A (is) 2006-05-04
KR20060123739A (ko) 2006-12-04
WO2005047270A3 (en) 2005-09-22
AU2004289694B2 (en) 2010-05-13
CN1922156A (zh) 2007-02-28
JP2007510741A (ja) 2007-04-26
WO2005047270A2 (en) 2005-05-26
US20090074890A1 (en) 2009-03-19
DE602004031667D1 (de) 2011-04-14
BRPI0416319A (pt) 2007-01-09
IL175522A0 (en) 2006-09-05

Similar Documents

Publication Publication Date Title
NO20062676L (no) Substituerte triazoler som natriumkanalblokkere
JO2480B1 (en) Triple aryl substituted with aryl as a sodium channel blocking agent
DK0766672T3 (da) Arylsulfonamido-substituerede hydroxamsyrer som matrixmetallopreteinase-inhibitorer
MX2009004475A (es) Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma.
WO2007145922A3 (en) Benzazepinones as sodium channel blockers
WO2005030766A8 (en) Phenyl - carboxamide compounds useful for treating pain
MXPA05009611A (es) Piperidinas sustituidas como nuevos inhibidores de mdm2-p53.
GEP20125389B (en) Substituted pyrazole and triazole compounds as ksp inhibitors
TW200800951A (en) Substituted imidazole compounds as KSP inhibitors
WO2010115184A3 (en) Hydroxythienoquinolones and related compounds as anti-infective agents
WO2004011477A3 (en) 6,11-4-carbon bridged ketolides
EA201071395A1 (ru) Ингибитор толерантности к анальгетику
MXPA05013151A (es) 3-fluoro-piperidinas como antagonistas de n-metil-d-aspartato/nr2b.
WO2006009893A3 (en) Cancer chemotherapy
TW200714596A (en) Isotopically substituted proton pump inhibitors
WO2005037213A3 (en) Antiinflammatory inhibitors of respiratory burst in adherent neutrophils
WO2007047881A3 (en) Method for treating neuropathic pain
MX2022011240A (es) Azálidos de urea inmunomoduladores.
WO2008006236A3 (en) Benzimidazoles as cooling compounds
DOP2004000850A (es) Triazoles sustituidos con biarilo como bloqueantes del canal de sodio
MX2023011554A (es) Composicion farmaceutica para la prevencion o tratamiento de enfermedad inflamatoria intestinal que actua como un antagonista funcional para s1pr1 y s1pr4.
WO2023217800A3 (en) Synthesis of glycosylated hydroxytryptamine compounds and methods of their use
WO2020176610A8 (en) Method for treating a multiple myeloma
BRPI0507837A (pt) métodos e composições para a administração intravenosa de compostos relacionados a inibidores de bomba de prótons
TH77894B (th) "เฮพทา-,ออคทา-และโนนาเพนไทด์ ที่มีการออกฤทธิ์ เชิงแอนทีแองกิโอจีนิค"

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application